Evidence map›Paper›PMID 40542203›Full record

ArticleNPJ precision oncology2025

Upregulation of POLE and proficient DNA repair are features of CIC::DUX4 sarcomas.

Nathan D Seligson, Anjali Paragji, Feha Shahalam, Binyam Yilma, James L Chen

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathan D SeligsonDepartment of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL, USA.
Anjali ParagjiDepartment of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL, USA.
Feha ShahalamDepartment of Pharmacotherapy and Translational Research, The University of Florida, Jacksonville, FL, USA.
Binyam YilmaTempus AI Inc., Chicago, IL, USA.
James L ChenTempus AI Inc., Chicago, IL, USA. James.Chen@osumc.edu.

Funding

UF COP N/AUFHJ CTR N/A
6 · The paper itself

Abstract

cic:DUX4 translocation-positive sarcomas (CDS) are rare, highly proliferative tumors associated with chemotherapy resistance. Without a clear understanding of the molecular pathways driving CDS, no effective treatment regimens have been developed. Here, we identify protection against DNA damage through upregulation of POLE and DNA repair pathways specific to CDS. These data may explain the high proliferation rate and chemotherapy resistance of these tumors and suggest targeted treatment strategies for CDS.

Identifiers

PMID40542203
PMCPMC12181340

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.